OptimizeRx (OPRX)

• Market cap: $94.9M
• 1 day: -4.63%
• 5 days: -4.10%
• 1 month: 0.78%
• 3 months: -34.06%
• 6 months: -55.18%
• Year to date: -63.32%
• 1 year: -47.29%
• 5 years: -41.48%
• 10 years: -50.48%
• Sector: Industrials
• Industry: Business Services

About: OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Employees: 136

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 27

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

4.6% less ownership

Funds ownership: 72.14% [Q2] → 67.54% (-4.6%) [Q3]

8% less funds holding

Funds holding: 92 [Q2] → 85 (-7) [Q3]

28% less capital invested

Capital invested by funds: $132M [Q2] → $95.5M (-$36.3M) [Q3]

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

95% less call options, than puts

Call options by funds: $7K | Put options by funds: $140K

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 3% downside
• Avg. target: $8.80 71% upside
• High target: $16 211% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

RBC Capital Sean Dodge 50% 1-year accuracy 5 / 10 met price target	36% upside $7	Outperform Maintained	14 Nov 2024
Roth MKM Richard Baldry 43% 1-year accuracy 3 / 7 met price target	211% upside $16	Buy Reiterated	14 Nov 2024
Stifel David Grossman 0 / 0 met price target	55% upside $8	Buy Maintained	14 Nov 2024
Barclays Stephanie Davis 43% 1-year accuracy 3 / 7 met price target	3% downside $5	Equal-Weight Maintained	14 Nov 2024
JMP Securities Constantine Davides 0 / 0 met price target	55% upside $8	Market Outperform Maintained	14 Nov 2024